Autolus Therapeutics PLC
NASDAQ:AUTL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tanger Factory Outlet Centers Inc
NYSE:SKT
|
US |
Autolus Therapeutics PLC
Tax Provision
Autolus Therapeutics PLC
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Tax Provision
-$2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Tax Provision
-£16.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Tax Provision
$2.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Tax Provision
-£17m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-5%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Tax Provision
£1.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
32%
|
CAGR 10-Years
-11%
|
|
|
Niox Group PLC
LSE:NIOX
|
Tax Provision
-£4.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
Glance View
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.
See Also
What is Autolus Therapeutics PLC's Tax Provision?
Tax Provision
-2m
USD
Based on the financial report for Dec 31, 2025, Autolus Therapeutics PLC's Tax Provision amounts to -2m USD.
What is Autolus Therapeutics PLC's Tax Provision growth rate?
Tax Provision CAGR 1Y
-29%
Over the last year, the Tax Provision growth was -29%.
